Net interest expenditure was $68 million, and the adjusted tax rate was 22.2 % in the quarter. On a GAAP basis, the fourth-quarter tax rate was 21.6 %. Fourth-quarter diluted earnings per share were $0.70 on a GAAP basis. Adjusted diluted income per share, excluding intangible asset amortization expense and other specified products, were $0.82. Essential Events from the 4th Quarter This early morning, AbbVie announced completion of its Phase 3 hepatitis C virus studies; including top-line outcomes from four remaining registrational HCV trials: TURQUOISE-II, PEARL-II, PEARL-III, and PEARL-IV trials. Results from the TURQUOISE-II research, which examined treatment of HCV in 380 sufferers with cirrhosis, a difficult-to-treat people, showed that patients treated for 12 weeks with the AbbVie mixture accomplished 92 % sustained virologic response at 12 weeks post treatment .Researchers initial tested the gel’s performance pre-contact, by applying it to three monkeys who were exposed to HIV twice a full week for seven weeks. By the final end, two of the three remained HIV-free, weighed against just one out of 10 monkeys in a group that received an inactive placebo gel. The team then tested whether the gel could drive back HIV infection after exposure, using six monkeys subjected to HIV twice weekly for two and a half months. Through the use of the gel three hours after exposure, researchers were able to protect five of the six monkeys from HIV an infection.